Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-09-12
2006-09-12
Monshipouri, Maryam (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000, C435S069100
Reexamination Certificate
active
07105485
ABSTRACT:
The invention relates to an improved method for predicting the onset of, diagnosing, prognosticating and/or treating dementing diseases. The method comprises determining the level of heme oxygenase-1 suppressor (HOS) activity and/or factor in tissue or body fluid obtained from a patient, and comparing said level with the corresponding level of HOS activity and/or factor in corresponding tissue or body fluid obtained from at least one control person. The tissue or body fluid is suitably blood, plasma, lymphocytes, cerebrospinal fluid, urine, saliva, epithelia or fibroblasts. The method is useful where the dementing disease is any of Alzheimer Disease, Age-Associated Cognitive Decline, Mild Cognitive Impairment, Parkinson disease with dementia, Progressive Supranuclear Palsy, Vascular (i.e. multi-infarct) Dementia, Lewy Body Dementia, Huntington's Disease, Down's syndrome, normal pressure hydrocephalus, corticobasal ganglionic degeneration, multisystem atrophy, head trauma, neurosyphilis, Creutzfeld-Jacob disease and other prion diseases, HIV and other encephalitides, and metabolic disorders such as hypothyroidism and vitamin B12 deficiency. The method may also prove useful in differentiating the “pseudodementia” of depression from Alzheimer disease.
REFERENCES:
Abraham, N.G. “Quantitation of heme oxygenase (HO-1) copies in human tissue or body fluids by competitive RT/PCR”, in Methods in Molecular Biology, (1998) vol. 108:Free Radical and Antioxidant Protocols(Armstrong, D., ed.),pp. 199-209, Humana Press Inc., Totowa, NF.
Abraham, N.G., et al.,Cell Physiol. Biochem.,(1996), 129-168.
Applegate, L.A., et al., “Induction of heme oxygenase: a general response to oxidant stress in cultured mammalian cells”Cancer Res.,(1991), Feb. 1;51(3):974-978.
Balldin J., et al., “Dexamethasone suppression test and serum prolactin in dementia disorders.”,PsychiatrySep. 1983;143:277-81.
Beal, M.F., “Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses?”,Ann. Neurol.Feb. 1992;31(2):119-30.
Benzi, G. and Moretti, A., “Are reactive oxygen species involved in Alzheimer's disease?”,Neurobiol. AgingJul.-Aug. 1995;16, 4:661-674.
Berg, L., “Clinical dementia rating (CDR)”Psychopharmacology Bulletin, (1988), 24, pp. 637-639.
Blackford, R.C. and LaRue, A., “Criteria for diagnosing age-associated memory impairment: proposed improvements from the field”Dev. Neuropsychol., (1989), 5:295-306.
Chertkow, H. and Bergman, H. “Troubles cognitifs et diagnostic precoce de la demance” In, M. Arcand & R. Hebert (Eds.),Precis pratique de geriatrie(2e ed.)Ste-Hyacinthe/Paris: Edisem/Maloine, (1997) pp. 157-172.
Chomczynski P. and Sacchi N. “Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chlorophorm extraction”Analytical Biochem.(1987) 162:156-159.
Chomczynski, P., et al. “DNAzol: a reagent for the rapid isolation of genomic DNA.”BiotechniquesMar. 1997;22(3):550-3.
Chopra, V.S., et al. “A cellular stress model for the differential expression of glial lysosomal cathepsins in the aging nervous system”Exp. Neurol.Oct. 1997;147(2):221-228.
Chopra, V.S., et al. “Differential effects of cysteamine on heat shock protein induction and cytoplasmic granulation in astrocytes and glioma cells”Mol. Brain Res.Jul. 1995;31(1-2):173-184.
Church G.M. and Gilbert W. “Genomic sequencing”Proc. Natl. Acad. Sci. USA(1984) 81:1991-1995.
Crook, T., et al., “Age-associated memory impairment: proposed diagnostic criteria and measures of clinical change: report of a National Institute of Mental Health work group”Dev. Neuropsychol.(1986) 2:261-276.
Davis, R.E., et al.,Neurology(1996) A276.
Dawe, B., et al., “Concepts of mild memory impairment in the elderly and their relationship to dementia—a review”Intl. J. Geriat. Psychiatry(1992) 7:473-479.
de Leon, M.J., et al., “Abnormal cortisol response in Alzheimer's disease linked to hippocampal atrophy.”LancetAug. 13, 1988;2(8607):391-392.
Deramaudt, T.B., et al. “Negative regulation of human heme oxygenase in microvessel endothelial cells by dexamethasone”Proc. Soc. Exp. Biol. Med.Nov. 1999;222(2):185-193.
El-Ghar, S. Abo, et al., “Oxygen Free Radicals and Alzheimer Disease”Can. J. Neurol. Sci.22 (suppl. 1) S69, 1995 (Abst. #P133).
Famulari, A.L., et al., “The antioxidant enzymatic blood profile in Alzheimer's and vascular diseases. Their association and a possible assay to differentiate demented subjects and controls.”J. Neurological SciencesSep. 15, 1996;141(1-2):69-78.
Farlow, M., et al.,Lancet(1992) 340:453-454.
Feinberg AP and Vogelstein B. “A Technique for radiolabelling DNA restriction endonuclease fragments to high specific activity”Analytic Biochem.(1984) 137:266-267.
Feldman, H. “Diagnosis of Alzheimer's Disease”Oral Presentation at the Royal College of Medicine meetingSep. 1997 Vancouver, B.C. (no printed publication available).
Fillenbaum, G.G. and Smyer, M.A. “The development, validity, and reliability of the OARS multidimensional functional assessmane questionaire”J. Gerentology(1981) 36:428-434.
Fujiwara Noriko, et al. “Quinazoline derivatives suppress nitric oxide production by macrophages through inhibition of NOS II gene expression”,FEBS LettersOct. 21, 1996;395(2-3):299-303.
Fukuyama, R., et al., “Gene expression of ND4, a subunit of complex I of oxidative phosphorylation in mitochondria, is decreased in temporal cortex of brains of Alzheimer's disease patients.”Brain Res.Mar. 25, 1996;713(1-2):290-3.
Grossi, D., et al. “Senile dementias”II International Symposium(1988) Paris: John Libbey Eurotext. pp. 97-99.
Haxby J.V, et al. “Individual trajectories of cognitive decline in patients with dementia of the Alzheimer type”J. Clin. Exp. Neuropsychol.Jul. 1992;14(4):575-592.
Hughes, C.P., et al., “A new clinical scale for the staging of dementia”Br. J. Psychiatry(1982) 140:566-572.
Ihara N., et al. “Developmental changes of gene expression in heme metabolic enzymes in rat placenta”FEBS Letter(1998)439:163-167.
Kennard, M.L., et al., “Serum levels of the iron binding protein p97 are elevated in Alzheimer's disease”Nature MedicineNov. 1996;2(11):1230-1235.
Keyse, S.M., et al., “Heme oxygenase is the major 32-kDa stress protein induced in human skin fibroblasts by UVA radiation, hydrogen peroxide, and sodium arsenite”PNAS, (1989), 86:99-103.
Kral, V.A., “Senescent forgetfulness: benign and malignant”J. Can. Med. Assoc.(1962) 86:257-260.
Kutty R. Krishnan, et al. “Induction of heme oxygenase 1 in the retina by intense visible light: Suppression by the antioxidant dimethylthiourea”,PNAS, (1995):1177-1181.
Lannfelt, L., et al., “Decreased alpha-secretase-cleaved amyloid precursor protein as a diagnostic marker for Alzheimer's disease.”Nature Med.Aug. 1995;1(8):829-832.
Lavrosky, Y., et al. “Downregulation of the human heme oxygenase gene by glucocorticoids and identification of 56b regulatory elements”Biochem. Biophys. Res. Comm.(1996) 218:759-765.
Levy, R., “Aging-associated cognitive decline. Working Party of the International Psychogeriatric Association in collaboration with the World Health Organization.”International Psychogeriatrics(1994) Spring;6:63-68.
Mann, U., et al. “Heterogeneity in Alzheimer's disease: Progression rate segregated by distinct neuropsychological and cerebral metabolic profiles”J. Neurol. Neurosurg. Psychiatry(1992) 55:956-959.
Masuya Yoshiro, et al. “Involvement of the tyrosine phosphorylation pathway in induction of human heme oxygenase-1 by hemin, sodium arsenite, and cadmium chloride”Biochemistry, (1998)124:628-633.
Mawal Yogesh R., et al., “RT-P
Monshipouri Maryam
Schipper Hyman M.
The Sir Mortimer B. Davis - Jewish General Hospital
LandOfFree
HO-1 suppressor as a diagnostic and prognostic test for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with HO-1 suppressor as a diagnostic and prognostic test for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HO-1 suppressor as a diagnostic and prognostic test for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3554291